#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to recognize cannabinoid hyperemesis syndrome (CHS) as a legitimate diagnosis in patients presenting with severe, recurrent nausea and vomiting that paradoxically worsens with cannabis use, since early identification can prevent unnecessary diagnostic workups and emergency department visits. Understanding that CHS involves dysregulation of the endocannabinoid system helps providers counsel patients about dose-dependent risks and the potential for symptom escalation with continued use, enabling informed shared decision-making about cannabis cessation. This knowledge is particularly important given increasing cannabis potency and changing consumption patterns, which may increase the population at risk for developing this debilitating condition.
Cannabinoid hyperemesis syndrome (CHS), colloquially termed “scromiting,” is a paradoxical condition where chronic cannabis use triggers severe cyclic nausea and vomiting despite the drug’s known antiemetic properties in other contexts. Current evidence suggests that prolonged cannabinoid exposure dysregulates the endocannabinoid system, disrupting the body’s natural homeostatic control of nausea and vomiting, with symptom onset appearing to correlate with cumulative exposure and individual threshold effects. This syndrome presents a clinical challenge because patients often continue cannabis use seeking symptom relief, creating a counterproductive cycle that can result in severe dehydration, electrolyte abnormalities, and significant morbidity if the underlying cannabis dependence is not addressed. The condition predominantly affects chronic users of high-potency products, making it increasingly relevant as cannabis concentrates and edibles become more widely available. Clinicians should maintain a high index of suspicion for CHS in patients with intractable nausea and vomiting, particularly those with heavy cannabis use, and recognize that cessation of cannabis is the definitive treatment rather than continued use or conventional antiemetics alone. For patients considering or using cannabis therapeutically, awareness of CHS risk and discussion of individual vulnerability factors should inform shared decision-making around dosage, frequency, and product potency.
“Cannabinoid Hyperemesis Syndrome is real and I see it regularly in my practice, but it’s almost entirely preventable through proper patient education about consumption patterns and dose limits before someone crosses that threshold into daily heavy use.”
💊 Cannabinoid hyperemesis syndrome (CHS) represents a paradoxical and poorly understood adverse effect in regular cannabis users, wherein chronic consumption leads to severe cyclic vomiting despite the drug’s well-known antiemetic properties in other contexts. The proposed mechanism involving endocannabinoid system dysregulation is plausible but remains incompletely characterized, and individual susceptibility appears to depend on multiple factors including dose, frequency, potency of products used, and possibly genetic predisposition. Clinicians should maintain a high index of suspicion for CHS in patients presenting with recurrent nausea and vomiting who report regular cannabis use, particularly given that the condition is often misdiagnosed as primary gastrointestinal or neurologic disease, leading to unnecessary testing and delayed recognition. The only established treatment remains complete cannabis cessation, which typically resolves symptoms within days to weeks, making careful patient counseling about
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: